About Us

Prothena is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases.

We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our diversified portfolio is designed to make a significant impact on rare peripheral amyloid and neurodegenerative diseases.

Proteins that misfold and aggregate to form amyloid are associated with more than 25 human diseases that can gravely damage organs. Amyloid can affect any organ in the body, including the brain and peripheral organs. For example, the misfolding and aggregation of the amyloid beta (Aβ) peptide leads to a build-up of amyloid protein in the brain, which most scientists believe is the primary cause of Alzheimer’s disease. Transthyretin amyloidosis (ATTR amyloidosis), a rare, progressive and fatal disease, is characterized by deposition of aggregated misfolded transthyretin protein in peripheral organs such as the heart and nerves.

Prothena leverages insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases.

Scientifically, we focus on genetically-associated and biologically-validated targets implicated in disease. We have extensive and deep understanding of the pathology that is fundamental to the cause and progression of rare peripheral amyloid and neurodegenerative diseases and apply our expertise to develop new therapies that target their underlying cause. We optimally target misfolded proteins to achieve clinical benefit across a number of indications, focusing on proteins like Aβ, tau, alpha-synuclein and transthyretin.

Decades of our own investigation augmented by the work of others have elucidated that antibodies that target the appropriate epitope, with the optimal binding strength in the context of the right clinical design with appropriate endpoints in the right patient population, can result in meaningful clinical benefit.

Increasingly, these elements are aligning, and because of advances in our knowledge that informs the basic, clinical and regulatory sciences, we find ourselves with an expanding pipeline of  investigational therapies in this space.

While we are modality agnostic, we have deep expertise in antibody targeting and leverage insights and understanding around neurological dysfunction and the biology of misfolded proteins to develop a diverse pipeline that also includes small molecule and vaccine approaches. Clinical data has revealed a path forward that makes developing new therapies possible, targeting the pathogenic proteins that underlie progressive and fatal neurodegenerative and peripheral amyloid diseases to address areas of high unmet need for patients.

We capitalize on a foundation of internal discovery efforts augmented by collaborations with academic and industry partners and business development activities to build upon our internally generated pipeline.


Prothena’s leadership team has a track record for profound scientific discoveries and bringing forth new treatments that have become leading commercial products in their therapeutic categories.

Gene G. Kinney, Ph.D.

President and Chief Executive Officer, Director

Hideki Garren, M.D., Ph.D.

Chief Medical Officer

Carol D. Karp

Chief Regulatory Officer

Michael J. Malecek

Chief Legal Officer

Tran B. Nguyen

Chief Financial Officer and Chief Strategy Officer

Brandon Smith

Chief Operating Officer

Karin L. Walker

Chief Accounting Officer

Wagner M. Zago, Ph.D.

Chief Scientific Officer

Board of Directors


Prothena is focused on accelerating pioneering science from bench to bedside with a singular focus on creating a better future for people with rare peripheral amyloid and neurodegenerative diseases.

Our team has deep scientific and operational expertise and a track record of moving big ideas forward. We are advancing a robust portfolio across modalities leveraging our deep expertise in neurological dysfunction, antibody targeting and the biology of misfolded proteins. We collaborate and engage with our multifaceted network of scientists, key opinion leaders, drug development specialists, regulatory experts and patient associations to accelerate insights into actionable and creative ways to advance the best science to patients.

We continually seek to engage with innovators actively researching bold scientific ideas. We collaborate across therapeutic modalities and across the continuum of neurodegenerative diseases where we believe we can deliver value. We invest in and forge partnerships with emerging biotech companies and academic research institutions to accelerate the development of new medicines. We are committed to cultivating long-term relationships and strategic alliances with the opportunity for shared success.

Together with our network of collaborators, we are creating a path for the most promising neuroscience to be translated into treatments.

For more information on partnering or collaborating with Prothena, contact us at collaborate@prothena.com.


Our scientific legacy began with Athena Neurosciences, which was founded in 1986. Athena scientists made significant discoveries that have advanced our understanding of the biology of Alzheimer’s disease. Particularly impactful were the fundamental discoveries elucidating the roles amyloid, gamma secretase, and beta secretase play in the disease. These findings led to the development of a drug discovery and development organization, which generated multiple clinical candidates that have been and continue to be, tested in Alzheimer’s disease.

These same scientists also pioneered significant scientific discoveries with cell adhesion molecules, leading to the discovery, development and commercialization of Tysabri® (natalizumab), which is FDA approved for the treatment of relapsing forms of multiple sclerosis and marketed by Biogen. Athena was acquired by Elan Corporation, plc in 1996, and its discovery and development activities were incorporated into Elan.

Prothena was established in December 2012 when it separated from Elan Corporation, plc with a substantial portion of its drug discovery platform. Our ordinary shares began trading on the Nasdaq Global Market under the symbol “PRTA” and are currently traded on the Nasdaq Global Select Market.

Today, Prothena is drawing on our legacy and deep expertise in protein dysregulation to build a pipeline of investigational compounds that could deliver innovative therapies for patients.